Abstract
We have used a peptide derived from Acanthamoeba castellanii (ACA) to treat the relapsing phase of EAE that develops in SJL mice following immunization with the PLP 139-151 peptide. The native sequence of the ACA 81-95 peptide that shares key residues with the PLP 139-151 peptide is weakly encephalitogenic in SJL mice but is not recognized by antiserum from SJL mice immunized with PLP 139-151. A single amino acid change to the ACA 81-95 peptide sequence significantly enhanced its encephalitogenicity. When administered to SJL mice as a nonlinear peptide octamer, the modified ACA peptide prevented relapsing episodes of EAE in SJL mice previously immunized with the PLP 139-151 encephalitogenic peptide.
Original language | English (US) |
---|---|
Pages (from-to) | 46-52 |
Number of pages | 7 |
Journal | Journal of Neuroimmunology |
Volume | 274 |
Issue number | 1-2 |
DOIs | |
State | Published - 2014 |
Externally published | Yes |
Keywords
- Peptide mimic
- Peptide octamer
- Prevention of relapsing disease
- Relapsing EAE
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Neurology
- Clinical Neurology